Who founded Grannus Therapeutics?

Grannus Therapeutics was founded by Brian Blagg, Sanket Mishra in 2020.

Who are Grannus Therapeutics's investors?

Grannus Therapeutics's investors include 1842, Elevate Ventures.

How much funding has Grannus Therapeutics raised?

Grannus Therapeutics has disclosed $1.8M raised across 2 rounds.

Where is Grannus Therapeutics headquartered?

Grannus Therapeutics is headquartered in Indianapolis, US.

Grannus Therapeutics

Indianapolis, US · Founded 2020 · United States corporation · 2 known investors

Find your way into Grannus Therapeutics

Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.

Biotech Healthtech

Founders & leadership

Grannus Therapeutics was founded in 2020 by Brian Blagg and Sanket Mishra.

Brian BlaggCo-founder

Sanket MishrainCo-Founder and VP preclinical R&D

John FoglesongNamed on SEC filing

James ThompsonNamed on SEC filing

Investors · 2

1842Notre Dame

Elevate VenturesIndianapolis · $20K – $2M

Reported raises · per SEC filings

Form D private placements

$1.8M disclosed across 2 rounds · 2022–2023

▶$800KraisedJan 2024 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John FoglesongExecutive Officer, Director
Brian BlaggDirector

Offering amount: $800K
Amount sold: $800K
Minimum investment: $250K
First sale: Nov 2023
Incorporated: Corporation, United States, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$950KraisedJan 2022 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John FoglesongExecutive Officer, Director
James ThompsonDirector
Brian BlaggDirector

Offering amount: $1M
Amount sold: $950K
Minimum investment: $35K
First sale: Jan 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Transcode Therapeutics8 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.

Linnaeus Therapeutics5 shared keywordsClinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.

Marengo Therapeutics5 shared keywordsMarengo Therapeutics is a clinical-stage biotech company developing TCR-targeting antibodies that activate specific T cell subsets by targeting Variable β (Vβ) chain variants of the T cell receptor. Its approach aims to modulate the immune system to treat cancer and other diseases.

Northwest Biotherapeutics4 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.

Companies competing with Grannus Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Grannus Therapeutics do?: Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.
Who founded Grannus Therapeutics?: Grannus Therapeutics was founded by Brian Blagg, Sanket Mishra in 2020.
Who are Grannus Therapeutics's investors?: Grannus Therapeutics's investors include 1842, Elevate Ventures.
How much funding has Grannus Therapeutics raised?: Grannus Therapeutics has disclosed $1.8M raised across 2 rounds.
Where is Grannus Therapeutics headquartered?: Grannus Therapeutics is headquartered in Indianapolis, US.